Early Release

Early Release / Review Article

Prof. Dr. Abdülkadir Noyan: Professional and Academic Aspects

Turhan Ada

Most Read

  1. Pneumococcal Vaccine as One of the Immunization Coverage Targets for Adulthood Vaccines: A Consensus Report of the Study Group for Adult Immunization of the Turkish Society of Clinical Microbiology and Infectious Diseases
  2. Does Hepatitis B Affect Erectile Dysfunction and Lower Urinary Tract Symptoms?
  3. HIV Infection in Turkey: How Close Are We to the Target?
  4. Evaluation of HBeAg-Negative Chronic Hepatitis B Patients Who Had Undergone Liver Biopsy in Accordance With the Guidelines
  5. Diagnosis, Treatment and Prevention of Diabetic Foot Wounds and Infections: Turkish Consensus Report
  6. When to Stop Antiviral Therapy in Chronic Hepatitis B
  7. Mycoplasma hominis and Ureaplasma urealyticum: Their Role in Urogenital System Infections and Retrospective Evaluation of Antibiotic Resistance Rates
  8. Crimean-Congo Haemorrhagic Fever: Treatment and Use of Ribavirin
  9. Modern Diagnostic Methods Used in Bacteriology: Rapid and Effective
  10. Analysis of HIV/AIDS-Related Stigma and Discrimination in Turkey: Results of the People Living With HIV Stigma Index

Volume 23, Issue 2

Original Article

Evaluation of Treatment Results of Patients with Chronic Hepatitis C Followed for Five Years

Sıla Çetin Akhan
Affiliations
  • Kocaeli Üniversitesi, Tıp Fakültesi, İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, Kocaeli, Türkiye
,
Aynur Aynıoğlu
Affiliations
  • Kocaeli Üniversitesi, Tıp Fakültesi, İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, Kocaeli, Türkiye
,
Elif Sargın-Altunok
Affiliations
  • Kocaeli Üniversitesi, Tıp Fakültesi, İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, Kocaeli, Türkiye
,
Murat Sayan
Affiliations
  • Kocaeli Üniversitesi, Tıp Fakültesi, Merkez Laboratuvarı, Polimeraz Zincir Reaksiyonu Ünitesi, Kocaeli, Türkiye
  • Chronic hepatitis C
  • hepatitis C virus genotype 1
  • Pegylated interferonα
  • ribavirin

Abstract

Objective: In this study, treatment results of patients with chronic hepatitis C (CHC) infected with hepatitis C virus (HCV) genotype 1 followed for five years were evaluated retrospectively. 

Methods: Between January 2004 and January 2010, 245 patients treated for CHC were evaluated. Of these, 98 treatment naive patients, who did not skip both pegylated interferon (PEG IFN) and ribavirin doses for more than three consecutive weeks, due to side effects or other reasons, who completed the treatment course, attended regular follow up appointments and with complete follow up data, were included. HCV RNA-positive patients with chronic liver disease established by liver biopsy were diagnosed as CHC, and started on PEG IFN and ribavirin. Patients, whose end of treatment responses (ETR) were obtained without a sustained virological response (SVR), received a second course of treatment with PEG IFN-α 2b plus ribavirin if they had been treated with PEG IFN-α 2a previously, or vice versa. 

Results: Of the 98 patients, 58 received PEG IFN-α 2a (Group 1) and 31 received PEG IFN-α 2b (Group 2) initially. Nine patients began with one type of PEG IFN and continued with the other type due to intolerance (Group 3). By the end of 3 months, no statistically significant difference was noted between Groups 1 and 2 regarding early virological response (EVR) (p=0.12,  p=0.08, p=0.04). There was a statistically significant difference between these groups regarding SVR (p=0.007, p=0.85, p<0.001). Compared to the first two groups, the Group 3 results were significantly different for both EVR and SVR, indicating treatment failure. No statistically significant difference was noted between groups after the second course of treatment. Regardless of the type of IFN used initially, the SVR rate was 48% (47/98) for the first course and 58% (11/19) for the second course of treatment.

Conclusions: A SVR may be obtained after a second course of treatment in almost 50% of the CHC patients without a SVR after the first course. Therefore, extension of the treatment from 48 weeks to 72 weeks may be considered in patients in whom an ETR was obtained. 

  • 39-43
  • 10.5152/kd.2010.13
  • July 23, 2019
  • 1959
  • 711
Download as PDF
  • This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License. CC BY-NC
Volume 37, Issue 3 Volume 37, Issue 2 Volume 37, Issue 1 Volume 36, Issue 4 Volume 36, Supplement 1 Volume 36, Issue 3 Volume 36, Issue 2 Volume 36, Issue 1 Volume 35, Issue 4 Volume 35, Issue 3 Volume 35, Issue 2 Volume 35, Issue 1 Volume 34, Issue 3 Volume 34, Issue 2 Volume 34, Issue 1 Volume 33, Issue 3 Volume 33, Issue 2 Volume 33, Issue 1 Volume 32, Issue 3 Volume 32, Supplement 1 Volume 32, Supplement 2 Volume 32, Issue 2 Volume 32, Issue 1 Volume 31, Issue 3 Volume 31, Issue 2 Volume 31, Supplement 1 Volume 31, Issue 1 Volume 30, Issue 3 Volume 30, Issue 2 Volume 30, Supplement 1 Volume 30, Issue 1 Volume 29, Issue 3 Volume 29, Issue 2 Volume 29, Issue 1 Volume 28, Supplement 1 Volume 28, Issue 3 Volume 28, Issue 2 Volume 28, Issue 1 Volume 27, Supplement 1 Volume 27, Issue 3 Volume 27, Issue 2 Volume 27, Issue 1 Volume 26, Issue 3 Volume 26, Supplement 1 Volume 26, Issue 2 Volume 26, Issue 1 Volume 25, Issue 3 Volume 25, Issue 2 Volume 25, Issue 1 Volume 24, Issue 3 Volume 24, Issue 2 Volume 24, Issue 1 Volume 23, Issue 3 Volume 23, Issue 2 Volume 23, Issue 1 Volume 22, Issue 3 Volume 22, Issue 2 Volume 22, Issue 1 Volume 21, Issue 3 Volume 21, Supplement 2 Volume 21, Supplement 1 Volume 21, Issue 2 Volume 21, Issue 1 Volume 20, Issue 3 Volume 20, Supplement 2 Volume 20, Issue 2 Volume 20, Issue 1 Volume 20, Supplement 1 Volume 19, Issue 3 Volume 19, Issue 2 Volume 19, Issue 1 Volume 18, Issue 3 Volume 18, Supplement 1 Volume 18, Issue 2 Volume 18, Issue 1 Volume 17, Issue 3 Volume 17, Issue 2 Volume 17, Issue 1 Volume 16, Issue 3 Volume 16, Issue 2 Volume 16, Issue 1 Volume 1, Supplement 1 Volume 15, Issue 3 Volume 15, Issue 2 Volume 15, Issue 1 Volume 14, Issue 3 Volume 14, Issue 2 Volume 14, Issue 1 Volume 13, Issue 3 Volume 13, Issue 2 Volume 13, Supplement 1 Volume 13, Issue 1 Volume 12, Issue 3 Volume 12, Issue 2 Volume 12, Issue 1 Volume 11, Issue 3 Volume 11, Issue 2 Volume 11, Supplement 1 Volume 11, Issue 1 Volume 10, Issue 3 Volume 10, Issue 2 Volume 10, Issue 1 Volume 9, Issue 3 Volume 9, Issue 2 Volume 9, Issue 1 Volume 8, Issue 3 Volume 8, Issue 2 Volume 8, Issue 1 Volume 6, Issue 3 Volume 7, Issue 1 Volume 7, Issue 2 Volume 7, Issue 3 Volume 4, Issue 3 Volume 5, Issue 1 Volume 5, Issue 2 Volume 5, Issue 3 Volume 6, Issue 1 Volume 6, Issue 2 Volume 3, Issue 1 Volume 3, Issue 2 Volume 3, Issue 3 Volume 4, Issue 1 Volume 4, Issue 2 Volume 1, Issue 2 Volume 2, Issue 1 Volume 2, Issue 2 Volume 2, Issue 3 Volume 1, Issue 1